Sangamo Therapeutics, Inc.
ENGINEERED CLEAVAGE HALF-DOMAINS

Last updated:

Abstract:

Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.

Status:
Application
Type:

Utility

Filling date:

4 Oct 2021

Issue date:

12 May 2022